EU approves Gilead's new injection for preventing HIV

Gilead Sciences has received European Commission marketing authorization for its twice-yearly HIV prevention injection, lenacapavir (Yeytuo), following its earlier U.S. approval. This highly effective pre-exposure prophylactic, projected to achieve over $4 billion in annual sales by 2029, faces U.S. insurer hesitancy due to its over $28,000 annual list price compared to generic alternatives, requiring country-specific pricing and reimbursement negotiations across the EU. The approval significantly expands Gilead's global market for this key drug, with further international regulatory filings and initiatives for low-income country access underway.

Analysis

Gilead Sciences (GILD) has secured a significant regulatory win with the European Commission's marketing authorization for its twice-yearly HIV prevention injection, lenacapavir, to be marketed as Yeytuo. This approval opens access to the 27 EU member states and other European nations, following its earlier U.S. approval as Yeztugo. The drug is a key asset for Gilead's growth pipeline, with analysts projecting annual sales to exceed $4 billion by 2029. Its strong clinical profile, demonstrating nearly 100% efficacy in trials, and the convenience of a twice-yearly injection provide a compelling value proposition. Furthermore, the EU approval was granted under an accelerated timeline and came with an additional year of market protection, enhancing its long-term commercial value. However, a critical headwind remains in pricing and market access. The U.S. list price of over $28,000 per year has led to hesitancy from some insurers, a challenge that will likely be replicated as Gilead enters pricing and reimbursement negotiations with individual national health systems across Europe. The company's global strategy also includes regulatory filings in other key markets and a plan for broad access in low- and middle-income countries, signaling a multi-tiered approach to maximizing the drug's global reach.

Key Decisions for Investors

• The EU approval significantly de-risks a key pipeline asset with blockbuster potential, reinforcing the long-term revenue growth outlook for Gilead.
• Investors should closely monitor upcoming announcements regarding pricing and reimbursement agreements in major EU countries, as these will be critical determinants for the pace of revenue uptake and the ability to meet the $4 billion peak sales forecast.
• The additional year of market exclusivity granted in the EU is a tangible positive that should be factored into valuation models, potentially increasing the net present value of future cash flows from this product.
• Given the pricing challenges highlighted in the U.S., consider the risk that net realized prices in Europe may fall below initial expectations, which could moderate the revenue ramp in the medium term.